let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma

BackgroundRenal cell carcinoma (RCC) is characterized by inherent resistance to chemotherapy. Earlier studies demonstrated that microRNAs (miRNAs) might be involved in the chemosensitivity of cancers. MicroRNA let-7, a putative tumor suppressor, is dysregulated in many cancers. Our study aims to investigate the exact role of let-7 in chemotherapy sensitivity of 5-fluorouracil (5-FU) in RCC.MethodsThe clinical significance of let-7b and let-7c expression in surgically resected specimens was assessed by qRT-PCR. Cell proliferation assay and colony formation assay were used to assess the survival of 786-O cells treated with let-7b or let-7c combined with 5-FU. Western blot was used to detect the expression of Akt2 and caspase-7. Luciferase assay was used to detect the direct binding of let-7b and let-7c to the 3′-untranslated region (UTR) of Akt2.ResultsExpression of let-7b and let-7c was significantly decreased in 32 paired clear cell renal cell carcinoma tissue specimens and the dysregulation of let-7b was associated with pathological grade. Transfection of let-7b or let-7c combined with 5-FU inhibited proliferation and potentiated the antitumor efficacies of 5-FU at tolerated concentration. let-7b and let-7c suppressed the luciferase activity of reporter plasmid containing the 3′-UTR of Akt2. Overexpression of let-7b and let-7c reduced Akt2 expression, and Akt2 inhibition enhanced the sensitivity to 5-FU by affecting apoptotic pathway.ConclusionsExpression of let-7b and let-7c was frequently decreased in clear cell renal cell carcinoma tissues. The dysregulation of let-7b and let-7c may be involved in chemoresistance of RCC cells to 5-FU by down-regulating Akt2.

[1]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[2]  Jie Fan,et al.  Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. , 2012, Biochemical and biophysical research communications.

[3]  Xiaohong Song,et al.  Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway , 2008, Apoptosis.

[4]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[5]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[6]  Y. Doki,et al.  Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma , 2012, Clinical Cancer Research.

[7]  L. O’Driscoll,et al.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma , 2009, BMC urology.

[8]  Jingai Zhu,et al.  microRNA expression profiling of the developing mouse heart. , 2012, International journal of molecular medicine.

[9]  M. Oya,et al.  Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. , 2003, The Journal of urology.

[10]  Jean-Jacques Patard,et al.  EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.

[11]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[12]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[13]  Jie Fan,et al.  Mechanism and function of decreased FOXO1 in renal cell carcinoma , 2012, Journal of surgical oncology.

[14]  Sun-Mi Park,et al.  Let‐7 modulates acquired resistance of ovarian cancer to Taxanes via IMP‐1‐mediated stabilization of multidrug resistance 1 , 2012, International journal of cancer.

[15]  Sun-Mi Park,et al.  The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.

[16]  V. Leblanc,et al.  Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells. , 2013, Gynecologic oncology.

[17]  Jia Yu,et al.  Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. , 2014, Die Pharmazie.

[18]  C. Luo,et al.  Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells , 2012, Brain Research.

[19]  J. Bellmunt,et al.  Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. , 2014, European journal of cancer.

[20]  R. Recker,et al.  let-7 MicroRNAs Induce Tamoxifen Sensitivity by Downregulation of Estrogen Receptor α Signaling in Breast Cancer , 2011, Molecular medicine.

[21]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[22]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[23]  C. Bokemeyer,et al.  Chemotherapy for renal cell carcinoma. , 1999, Anticancer research.

[24]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[25]  Xiaohong Song,et al.  Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. , 2009, Cancer letters.

[26]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[27]  A. Toker,et al.  Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. , 2009, Cellular signalling.

[28]  G. Z. Cheng,et al.  Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.

[29]  D. Jacqmin,et al.  The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. , 2006, Cancer research.